GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Quest Diagnostics Inc (NYSE:DGX) » Definitions » Beneish M-Score

Quest Diagnostics (Quest Diagnostics) Beneish M-Score : -2.58 (As of Apr. 26, 2024)


View and export this data going back to 1996. Start your Free Trial

What is Quest Diagnostics Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.58 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Quest Diagnostics's Beneish M-Score or its related term are showing as below:

DGX' s Beneish M-Score Range Over the Past 10 Years
Min: -2.85   Med: -2.62   Max: -2.35
Current: -2.58

During the past 13 years, the highest Beneish M-Score of Quest Diagnostics was -2.35. The lowest was -2.85. And the median was -2.62.


Quest Diagnostics Beneish M-Score Historical Data

The historical data trend for Quest Diagnostics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Quest Diagnostics Beneish M-Score Chart

Quest Diagnostics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.64 -2.35 -2.73 -2.85 -2.58

Quest Diagnostics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.69 -2.67 -2.53 -2.58 -2.58

Competitive Comparison of Quest Diagnostics's Beneish M-Score

For the Diagnostics & Research subindustry, Quest Diagnostics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Quest Diagnostics's Beneish M-Score Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Quest Diagnostics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Quest Diagnostics's Beneish M-Score falls into.



Quest Diagnostics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Quest Diagnostics for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0901+0.528 * 1.026+0.404 * 0.9959+0.892 * 0.9671+0.115 * 0.9829
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.8998+4.679 * -0.036405-0.327 * 1.0383
=-2.58

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Total Receivables was $1,322 Mil.
Revenue was 2366 + 2288 + 2295 + 2338 = $9,287 Mil.
Gross Profit was 771 + 736 + 754 + 792 = $3,053 Mil.
Total Current Assets was $2,228 Mil.
Total Assets was $13,954 Mil.
Property, Plant and Equipment(Net PPE) was $2,389 Mil.
Depreciation, Depletion and Amortization(DDA) was $448 Mil.
Selling, General, & Admin. Expense(SGA) was $1,643 Mil.
Total Current Liabilities was $2,298 Mil.
Long-Term Debt & Capital Lease Obligation was $4,293 Mil.
Net Income was 194 + 192 + 225 + 235 = $846 Mil.
Non Operating Income was 9 + 10 + -3 + 6 = $22 Mil.
Cash Flow from Operations was 154 + 527 + 207 + 444 = $1,332 Mil.
Total Receivables was $1,254 Mil.
Revenue was 2331 + 2333 + 2486 + 2453 = $9,603 Mil.
Gross Profit was 771 + 758 + 868 + 842 = $3,239 Mil.
Total Current Assets was $1,814 Mil.
Total Assets was $12,794 Mil.
Property, Plant and Equipment(Net PPE) was $2,384 Mil.
Depreciation, Depletion and Amortization(DDA) was $438 Mil.
Selling, General, & Admin. Expense(SGA) was $1,888 Mil.
Total Current Liabilities was $1,355 Mil.
Long-Term Debt & Capital Lease Obligation was $4,465 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(1322 / 9287) / (1254 / 9603)
=0.14235 / 0.130584
=1.0901

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(3239 / 9603) / (3053 / 9287)
=0.33729 / 0.328739
=1.026

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (2228 + 2389) / 13954) / (1 - (1814 + 2384) / 12794)
=0.669127 / 0.671877
=0.9959

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=9287 / 9603
=0.9671

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(438 / (438 + 2384)) / (448 / (448 + 2389))
=0.155209 / 0.157913
=0.9829

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(1643 / 9287) / (1888 / 9603)
=0.176914 / 0.196605
=0.8998

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((4293 + 2298) / 13954) / ((4465 + 1355) / 12794)
=0.472338 / 0.454901
=1.0383

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(846 - 22 - 1332) / 13954
=-0.036405

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Quest Diagnostics has a M-score of -2.58 suggests that the company is unlikely to be a manipulator.


Quest Diagnostics Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Quest Diagnostics's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Quest Diagnostics (Quest Diagnostics) Business Description

Traded in Other Exchanges
Address
500 Plaza Drive, Secaucus, NJ, USA, 07094
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Executives
Luis Diaz director C/O JOUNCE THERAPEUTICS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02138
Michael E Prevoznik officer: Corp VP, Legal & Compliance C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Catherine T. Doherty officer: SVP, Physician Services Bus. C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Timothy M Ring director C/O C.R BARD INC, 730 CENTRAL AVE, MURRAY HILL NJ 07974
Mark E Delaney officer: SVP & Chief Commercial Officer 500 PLAZA DRIVE, C/O QUEST DIAGNOSTICS INC, SECAUCUS NJ 07094
Mark A Gardner officer: SVP of Molecular Gen & Oncol 500 PLAZA DRIVE, C/O QUEST DIAGNOSTICS INC, SECAUCUS NJ 07094
Patrick Plewman officer: SVP for Diagnostic Services 500 PLAZA DRIVE, C/O QUEST DIAGNOSTICS INC, SECAUCUS NJ 07094
Karthik Kuppusamy officer: SVP, Clinical Solutions 500 PLAZA DRIVE, C/O QUEST DIAGNOSTICS INC, SECAUCUS NJ 07094
Michael J Deppe officer: VP, Corp. Controller & CAO 500 PLAZA DRIVE, C/O QUEST DIAGNOSTICS, SECAUCUS NJ 07094
Samer Abdul Samad officer: Executive Vice President & CFO 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Stephen H Rusckowski director, officer: President and CEO C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Tracey Doi director C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Gail R Wilensky director C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Mark Guinan officer: Senior Vice President & CFO C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Daniel Stanzione director C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094